Since the identification of a widespread transcriptional dysregulation that occurs in Huntington's disease (HD), histone deacetylase (HDAC) inhibition has been explored as a possible therapeutic strategy for this devastating disease. Studies using broadrange acting HDAC inhibitors have shown great promise in HD mouse models. Concomitantly, effects of inhibition of individual HDACs have been investigated, however, these experiments have been most frequently performed in worm, fly, and cell and less so in mouse models of HD. Previous reports have demonstrated disease modifying potential for both HDAC6 and SIRT2, which are the only tubulin deacetylases known in mammals. Nevertheless, the therapeutic value of these enzymes has not yet been explored in a complex mammalian system. This work addressed the question of what is the effect of genetically depleting either HDAC6 or SIRT2 in the R6/2 mouse model of HD on disease progression. After thorough characterisation of both Hdac6KO and Sirt2KO mice and expression of either mutation in the R6/2 mouse, a battery of physiological, behavioural and molecular readouts has clearly demonstrated that previous studies performed in invertebrate or cell culture systems do not translate to the mouse and that, therefore, HDAC6 and SIRT2 inhibition would not be of therapeutic value and should not be prioritised as a therapeutic strategy in HD.
|Date of Award
|1 May 2012
|Gillian Bates (Supervisor) & Michael Antoniou (Supervisor)